Company: OSRH
Filing Date: 2025-01-24
Form Type: S-4/A
Source: 0001213900-25-006139
Chunk: 513

Company: OSR Holdings, Inc.
Filing Date: 2025-01-24
Form: S-4/A
Chunk 513
---
. Dr. Cho has been Chairman and CEO of CG Pharmaceuticals, Inc. since October 2008 and previously served as Chairman and CEO of Hwail Pharmaceuticals Co. Ltd. from August 2013 to December 2022. Dr. Cho is the founder of Crystal Genomics and the former Chairman & President (July 2000 to March 2023). He has over 40 years of experience in biopharmaceutical industry covering from discovery of novel pharmaceuticals through R&D and commercialization. Dr. Cho has previously served as the executive Senior Vice President and Director of R&D Biotech Research Institute at LG Life Science (formerly LG Chem.) from 1984 to 2000. During his tenure, biopharmaceutical R&D at LG became the leading life science company in Korea where it grew from just a few research scientists to several hundred prior to his departure. He has successfully introduced 10 different recombinant products such as growth hormones of human, bovine, and porcine, hepatitis B vaccine, interferon alpha and gamma, GM -CSF, EPO, etc. Moreover, four drug candidates were licensed out to multinational pharmaceutical companies under his supervision and one of them is approved by FDA (US). On the basis of such achievements, Dr. Cho has received many awards 323 and acted as a member of governmental committees. He received his Ph.D. from University of Houston and worked as a post -docin Baylor College of Medicine. Dr. Cho is an author of more than 80 publications in books and journals including Nature, and an inventor of more than 200 patents filed. Dr. Cho is well qualified to serve as a director because of long -standingcareer experiences both as a biotech entrepreneur and the R&D Head of a major life sciences company in Korea (LG Group). Family Relationships There are no family relationships among any of the individuals who shall serve as the directors or executive officers of New OSR Holdings following the consummation of the Business Combination. Composition of the New OSR Holdings Board New OSR Holdings business and affairs will be managed under the direction of the New OSR Holdings Board. New OSR Holdings anticipates that the New OSR Holdings Board will consist of nine (9) members upon Closing of the Business Combination. Mr. Kuk Hyoun Hwang will serve as Chief Executive Officer and Chairman of the New OSR Holdings Board. Mr. Phil Geon Lee will serve as the lead independent director of New OSR Holdings. The primary responsibilities of the New OS